Business Context and Reporting Period
This Form 8-K Current Report from cbdMD, Inc. covers the period ending April 30, 2023. The filing primarily details the entry into a material definitive agreement for a public equity offering. The Company is an emerging growth company incorporated in North Carolina.
Key Financial Metrics and Transaction Details
- Offering Size: 1,350,000 shares of common stock.
- Offering Price: $2.10 per share.
- Net Proceeds: Approximately $2.5 million (after underwriting discounts, commissions, and estimated expenses).
- Over-Allotment Option: Underwriters granted a 45-day option to purchase up to 202,500 additional shares.
- Representative's Warrant: Issued to the underwriter to purchase up to 40,500 shares at an exercise price of $2.52 per share.
- Use of Proceeds: General working capital and selective mergers and acquisitions.
- Closing Date: May 3, 2023.
Note: This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics for the reporting period.
Material Changes
The primary material change is the capital raise described above. The filing does not provide comparative financial data against prior periods to quantify changes in operational metrics.
Guidance, Outlook, and Risks
- Management Commentary: Proceeds are designated for working capital and M&A activities.
- Lock-Up Agreements: The Company is subject to a 75-day lock-up period; officers, directors, and affiliates are subject to a 90-day lock-up period from the closing date.
- Insider Participation: One executive officer and one employee purchased up to $20,000 of shares at the public offering price.
- Risks: Forward-looking statements are subject to risks regarding the ability to satisfy closing conditions and other uncertainties detailed in prior SEC filings.
Investor Verification Checklist
- Verify the final closing date and total net proceeds received (May 3, 2023).
- Confirm whether the underwriters exercised the 45-day over-allotment option for 202,500 additional shares.
- Review the Company's subsequent filings for updates on the deployment of the $2.5 million in proceeds toward working capital or M&A.
- Monitor the expiration of the 75-day and 90-day lock-up periods for potential share sales by insiders.